Long-Acting Human Growth Hormone Receptor Antagonists Produced in E. coliand Conjugated with Polyethylene Glycol

Bibliographic Details
Title: Long-Acting Human Growth Hormone Receptor Antagonists Produced in E. coliand Conjugated with Polyethylene Glycol
Authors: Wang, Yue, Langley, Ries J., Tamshen, Kyle, Jamieson, Stephen M., Lu, Man, Maynard, Heather D., Perry, Jo K.
Source: Bioconjugate Chemistry; June 2020, Vol. 31 Issue: 6 p1651-1660, 10p
Abstract: Growth hormone (GH) is a peptide hormone that mediates actions through binding to a cell surface GH receptor (GHR). The GHR antagonist, B2036, combines an amino acid substitution at 120 that confers GHR antagonist activity, with eight additional amino acid substitutions. Conjugation to polyethylene glycol (PEG) increases the serum half-life of these proteins due to reduced renal clearance. Recombinant forms of GH and its antagonists are mainly produced in prokaryotic expression systems, such as E. coli. However, efficient production in E. coliis problematic, as these proteins form aggregates as inclusion bodies resulting in poor solubility. In the present study, we demonstrate that N-terminal fusion to a thioredoxin (Trx) fusion partner improves soluble expression of codon-optimized B2036 in E. coliwhen expressed at 18 °C. Expression, purification and PEGylation protocols were established for three GHR antagonists: B2036, B20, and G120Rv. Following purification, these antagonists inhibited the proliferation of Ba/F3-GHR cells in a concentration-dependent manner. PEGylation with amine-reactive 5 kDa methoxy PEG succinimidyl propionate yielded a heterogeneous mixture of conjugates containing four to seven PEG moieties. PEGylation significantly reduced in vitro bioactivity of the conjugates. However, substitution of lysine to arginine at amino acid residue 120 in B2036 improved the in vitro activity of the PEGylated protein when compared to unmodified PEGylated B2036. Pharmacokinetic analysis demonstrated that the circulating half-life of PEGylated B20 was 15.2 h in mice. Taken together, we describe an effective strategy to produce biologically active PEGylated human GHR antagonists.
Database: Supplemental Index
More Details
ISSN:10431802
15204812
DOI:10.1021/acs.bioconjchem.0c00208
Published in:Bioconjugate Chemistry
Language:English